Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Short term Debt (2016 - 2026)

Nutex Health (NUTX) has disclosed Short term Debt for 12 consecutive years, with $16.7 million as the latest value for Q1 2026.

  • For Q1 2026, Short term Debt rose 22.68% year-over-year to $16.7 million; the TTM value through Mar 2026 reached $16.7 million, up 22.68%, while the annual FY2025 figure was $13.3 million, 7.36% down from the prior year.
  • Short term Debt hit $16.7 million in Q1 2026 for Nutex Health, up from $13.3 million in the prior quarter.
  • Across five years, Short term Debt topped out at $31.4 million in Q3 2022 and bottomed at $2.7 million in Q1 2023.
  • Average Short term Debt over 5 years is $9.9 million, with a median of $7.9 million recorded in 2025.
  • Year-over-year, Short term Debt skyrocketed 17311.83% in 2022 and then tumbled 89.27% in 2023.
  • Nutex Health's Short term Debt stood at $12.5 million in 2022, then dropped by 13.85% to $10.8 million in 2023, then skyrocketed by 33.18% to $14.4 million in 2024, then decreased by 7.36% to $13.3 million in 2025, then increased by 25.43% to $16.7 million in 2026.
  • According to Business Quant data, Short term Debt over the past three periods came in at $16.7 million, $13.3 million, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.